Profile data is unavailable for this security.
About the company
AFT Pharmaceuticals Limited is a New Zealand-based multinational pharmaceutical company. The Company develops, markets, and distributes a portfolio of pharmaceutical products across a range of therapeutic categories, which are distributed across three pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. Its product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs. The Company develops and in-licenses products for sale by sales teams in Australia and New Zealand and in certain Southeast Asian markets, and out-licenses its products to local licensees and distributors in the rest of the world. Its products include A-Scabies, Allersoothe, Allersoothe Elixir, BecloClear, Candaderm, Coco-Scalp, Cromo-Fresh, Fenpaed, Fenpaed Double Strength, Ferro-Sachets, HYLO-FORTE, Itch-Soothe, Kiwisoothe, Lax-Tab, Loraclear, VitA-POS, and others.
- Revenue in NZD (TTM)236.25m
- Net income in NZD17.45m
- Incorporated1997
- Employees119.00
- LocationAFT Pharmaceuticals LtdLevel 1, 129 Hurstmere RoadAUCKLAND 0622New ZealandNZL
- Phone+64 94880232
- Fax+64 94880234
- Websitehttps://www.aftpharm.com/
Mergers & acquisitions
| Acquired company | AFT:NZC since announced | Transaction value |
|---|---|---|
| Pharma Dynamics (Pty) Ltd-Hospital Division Business | 2.48% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mediwound Ltd | 34.64m | -34.10m | 373.61m | 111.00 | -- | 4.50 | -- | 10.79 | -1.90 | -1.90 | 1.93 | 3.91 | 0.2475 | 4.59 | 3.69 | 188,576.60 | -24.36 | -35.38 | -35.12 | -48.39 | 18.53 | 32.18 | -98.43 | -71.55 | 2.48 | -- | 0.1416 | -- | 8.22 | -8.65 | -350.03 | -- | 51.27 | -- |
| Dawnrays Pharmaceutical (Holdings) Ltd | 266.02m | 42.17m | 378.71m | 1.12k | 8.99 | 0.4797 | 6.07 | 1.42 | 0.1323 | 0.1323 | 0.8344 | 2.48 | 0.2809 | 2.47 | 7.96 | 1,062,422.00 | 4.36 | 10.98 | 5.07 | 13.75 | 45.76 | 55.52 | 15.53 | 32.76 | 4.21 | -- | 0.0028 | 31.01 | -7.89 | 2.22 | 73.29 | 17.20 | 17.13 | 2.69 |
| AFT Pharmaceuticals Ltd | 236.25m | 17.45m | 387.78m | 119.00 | 22.36 | 3.94 | 19.46 | 1.64 | 0.1664 | 0.1664 | 2.25 | 0.9452 | 1.48 | 2.48 | 7.28 | 1,985,294.00 | 10.38 | 9.68 | 15.19 | 13.24 | 44.53 | 45.24 | 7.02 | 8.13 | 0.6944 | 9.01 | 0.2788 | 7.31 | 6.45 | 14.52 | -23.36 | 0.4473 | 1.16 | -- |
| Cutia Therapeutics | 59.82m | -112.85m | 393.78m | 298.00 | -- | 1.92 | -- | 6.58 | -1.70 | -1.70 | 0.8994 | 2.66 | 0.1908 | 2.55 | 5.57 | 848,679.80 | -36.00 | -- | -44.42 | -- | 34.92 | -- | -188.66 | -- | 2.92 | -- | 0.2774 | -- | 103.17 | -- | 77.91 | -- | -- | -- |
| Solara Active Pharma Sciences Ltd | 229.20m | -3.49m | 397.60m | 1.78k | -- | -- | 27.61 | 1.73 | -4.81 | -4.81 | 330.32 | -- | -- | -- | -- | 7,068,733.00 | -- | -3.27 | -- | -5.35 | 51.77 | 39.95 | -1.52 | -6.17 | -- | 0.7946 | -- | -- | -0.4003 | -0.5816 | 100.10 | -65.75 | -31.71 | -- |
| Opus Genetics Inc | 24.21m | -112.86m | 398.29m | 18.00 | -- | 37.75 | -- | 16.45 | -1.76 | -1.76 | 0.2952 | 0.0925 | 0.3825 | -- | 3.85 | 812,944.40 | -178.28 | -76.30 | -330.00 | -86.90 | -- | -- | -466.09 | -185.79 | -- | -- | 0.1518 | -- | -42.30 | -- | -476.13 | -- | -- | -- |
| Morepen Laboratories Ltd | 326.41m | 18.17m | 399.59m | 1.81k | 21.99 | -- | 14.84 | 1.22 | 1.81 | 1.81 | 32.65 | -- | -- | -- | -- | 9,850,214.00 | -- | 8.14 | -- | 12.81 | 33.71 | 31.83 | 5.61 | 5.91 | -- | 5.59 | -- | -- | 7.17 | 16.26 | 22.73 | 28.58 | 65.86 | -- |
| Bliss GVS Pharma Ltd | 157.15m | 20.03m | 402.09m | 966.00 | 20.18 | 1.94 | 14.93 | 2.56 | 10.31 | 10.31 | 80.97 | 107.18 | 0.6414 | 3.38 | 1.87 | 8,905,504.00 | 8.60 | 6.04 | 10.41 | 7.54 | 50.76 | 46.33 | 13.42 | 9.45 | 3.86 | 8.37 | 0.043 | 8.27 | 5.13 | 3.27 | 11.72 | -2.82 | 5.18 | 0.00 |
| Zhaoke Ophthalmology Ltd | 8.45m | -66.50m | 404.78m | 270.00 | -- | 0.9896 | -- | 47.91 | -0.5679 | -0.5679 | 0.0723 | 3.53 | 0.0159 | 1.38 | 9.25 | 135,773.70 | -12.50 | -38.02 | -14.65 | -41.79 | 49.28 | -- | -787.13 | -4,412.89 | 4.36 | -29.83 | 0.1373 | -- | 269.73 | -- | 38.32 | -- | 18.80 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Accident Compensation Corp.as of 30 Apr 2025 | 7.50m | 7.15% |
| Guardians of New Zealand Superannuationas of 30 Jun 2025 | 1.69m | 1.61% |
| Pengana Capital Ltd.as of 31 Oct 2025 | 1.02m | 0.98% |
| Salt Funds Management Ltd.as of 30 Apr 2025 | 768.12k | 0.73% |
| Kernel Wealth Ltd.as of 31 Jan 2026 | 97.33k | 0.09% |
| FCA Corp.as of 31 Dec 2025 | 46.00k | 0.04% |
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 35.59k | 0.03% |
